Glycopyrronium tosylate
Chemical compound
- US DailyMed: Glycopyrronium
administration
- D11AA01 (WHO)
- US: ℞-only[1]
- In general: ℞ (Prescription only)
- 1624259-25-1
- 121225724
- DBSALT002800
- 58902513
- 1PVF6JLU7B
- D10939
- ChEMBL3707243
- Interactive image
- O.Cc1ccc(cc1)S(=O)(=O)[O-].C[N+]2(C)CC[C@@H](C2)OC(=O)[C@@](O)(C3CCCC3)c4ccccc4
InChI
- InChI=1S/C19H28NO3.C7H8O3S.H2O/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;1-6-2-4-7(5-3-6)11(8,9)10;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;2-5H,1H3,(H,8,9,10);1H2/q+1;;/p-1/t17-,19-;;/m0../s1
- Key:UOWOLENSDISMPG-FFUVTKDNSA-M
Glycopyrronium tosylate, sold under the brand name Qbrexza among others, is a medication used for the treatment of primary axillary hyperhidrosis.[1][2][3]
It was approved for medical use in the United States in June 2018,[4] and in Japan in January 2022.[5]
References
- ^ a b "Qbrexza- glycopyrronium cloth". DailyMed. 17 January 2022. Retrieved 2 November 2022.
- ^ Nwannunu CE, Limmer AL, Coleman K, Shah R, Patel RR, Mui UN, Tyring SK (March 2019). "Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis". Skin Therapy Letter. 24 (2): 1–3. PMID 30970203.
- ^ Lamb YN (November 2019). "Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis: A Profile of Its Use". Clinical Drug Investigation. 39 (11): 1141–1147. doi:10.1007/s40261-019-00853-x. PMC 6877702. PMID 31571127.
- ^ "Drug Approval Package: Qbrexza (glycopyrronium)". U.S. Food and Drug Administration (FDA). 20 November 2018. Retrieved 1 November 2022.
- ^ "Maruho Launches Primary Axillary Hyperhidrosis Treatment". Maruho. 23 May 2022. Retrieved 2 November 2022.
- v
- t
- e
Other dermatological preparations (D11)
- Abrocitinib
- Aminobenzoate potassium
- Androgens (e.g., testosterone)
- Benzoylperoxide
- Brimonidine
- Caffeine
- Calcium gluconate
- Collagen
- Crisaborole
- Cromoglicic acid
- Delgocitinib
- Deoxycholic acid
- Diclofenac
- Dupilumab
- Estrogens (e.g., estradiol)
- Glycopyrronium bromide
- Glycopyrronium tosylate
- Hyaluronic acid
- Hydrogen peroxide
- Ivermectin
- Lebrikizumab
- Lokivetmab
- Magnesium sulfate
- Metandienone
- Nemolizumab
- Oclacitinib
- Oxymetazoline
- Povidone-iodine
- Pregnenolone acetate
- Progestogens (e.g., progesterone)
- Ruxolitinib
- Tiratricol
- Tralokinumab
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e